Meet Our Directors

The NuView Board of Directors has deep experience in development and growth of companies


Chairman and CEO

Mr. Crowe founded NuView Life Sciences in 2005 and serves as its Chairman and Chief Executive Officer. Mr. Crowe’s experience includes start-up and early-stage healthcare company development, strategic planning, capital formation, M&A, and public offerings. Mr. Crowe’s career includes senior executive sales and management positions for domestic and multi-national healthcare companies who introduced (a) diagnostic ultrasound in 1973 for Rohe Ultrasound – NV Philips Medical Systems; (b) nuclear magnetic resonance (NMR / MRI) in 1983 for Diasonics NMR Inc.; and (c) mobile positron emission tomography (PET) in 1999 for Mobile P.E.T. Systems Inc., Between 1986 and 1999 Mr. Crowe developed and operated outpatient medical service provider businesses, including diagnostic imaging facilities and gamma knife radio surgery facilities, and currently serves on the Board of Radiosurgical Centers of San Diego located at Scripps Memorial Hospital.



Mr. McCausland joined NuView Life Sciences as a director in October 2007. Over his 40-year career, Mr. McCausland has served in senior executive positions with Westinghouse Electric Corporation and Siemens. From 1997 through 2006, he served as president of the Siemens Medical Customer Solutions Group and during his tenure was instrumental at increasing revenues from $1 billion to over $4 billion. In addition to serving as an advisor to the Radiological Society of North America, the American College of Radiology, and several other healthcare companies, Mr. McCausland also serves as Chairman of the Siemens Foundation, dedicated to improving math and science education in high schools.



Mr. DeWald has served as the Chairman and CEO of Verity Financial Group, Inc. since 1992, where the primary focus has been in healthcare and technology sectors. He also serves as a director of public companies Healthcare Trust of America, Inc. and Targeted Medical Pharma, Inc. and as a non-executive Chairman of public company Integrated Healthcare Holdings, Inc. Mr. DeWald previously served as a director of Tenet Healthcare Corporation, ARV Assisted Living, Inc., Quality Systems, Inc., and Integrated Healthcare Holdings, Inc. From 1962 to 1991, DeWald was employed by KPMG LLP, where he served at various times as an audit partner, a member of their board of directors, as well as managing partner of the Los Angeles office.



Long and successful operating and investment career in venture capital, private equity investment, as well as new-venture and start-up operations, across a wide variety of industries, both domestic and international, including pharmaceutical drug development, genetic engineering, hospital management and distributed patient care, as well as a wide variety of industrial businesses including underground mining equipment, steel fabrication and finishing, security systems, consumer retail, newspaper publishing and parking.

Leonard is currently Chairman & CEO of Cheetah Robotic Parking Systems, a company he founded which is actively engaged in applying proprietary aerospace “swarm robot” technology to the parking industry.

Earlier, Leonard served as Chairman & CEO of Tapestry Pharmaceuticals, Inc. (NASDAQ listed). Prior to Tapestry, Leonard served as Chairman & CEO of NaPro BioTherapeutics, Inc. (NASDAQ listed). Both Tapestry Pharmaceuticals and NaPro BioTherapeutics were companies engaged in original research for the development of new chemical entities, from natural products, to treat cancer and related diseases. NaPro received three development, manufacturing and commercialization approvals from the FDA for its lead compound and marketed its finished product, through Abbott Laboratories in the United States and Europe, and through Faulding Pharmaceuticals in Australia and South East Asia.

Prior to founding and managing NaPro and Tapestry, Leonard was a Managing Partner of Adler & Shaykin (1983-1994), a private equity investment partnership organized to sponsor management leveraged buyouts. Through its two funds, Adler & Shaykin managed roughly $300 million of institutional and private capital. Adler & Shaykin acquired ten companies with total acquisition financing in excess of $2.4 billion. These companies had combined revenues in excess of $3.0 billion. The investors in the Adler & Shaykin funds consisted primarily of bank holding companies, public and private pension funds, insurance companies and individual private family offices.

Prior to forming Adler & Shaykin in 1983, Leonard was a Director and a member of the Investment Committee of Citicorp Venture Capital Ltd. and Citicorp Capital Investors, Inc., where he established and subsequently managed Citicorp’s first private equity fund dedicated to management leveraged buyouts. While at Citicorp, Leonard and his team invested on behalf of Citicorp in 12 separate private equity transactions. The combined sales volumes of these companies were approximately $1.8 billion. Within the venture capital group at Citicorp Leonard invested as a founding shareholder and Director in numerous technology and start-up ventures including Universal Health Services, Inc., which is today the second largest independent hospital chain in the United States.

Leonard was formerly either Chairman, CEO, Chairman of the Executive Committee,, Director, Principal Shareholder, Board Member, Committee Member and/or Founder of the following companies, over a span of some 45 years:

Adler & Tolkowsky, LLC
Best Products Co, Inc
The Chicago-Sun Times, Inc
Ecolaire, Inc
The Folger Adam Company
Harmony Parking Partners, Inc
Hollinger International (NYSE)
International Health Care
Iprivacy, Inc
Joy Technologies, Inc (NYSE)
Kimeragen, Inc
Mid-Atlantic Coca-Cola, Inc
Multiserve International
NaPro Biotherapeutics, Inc (NASDAQ)
Peterson Outdoor Advertising, Inc
Revlon, Inc (NYSE)
Trireme Systems, Inc
Tapestry Pharmaceuticals, Inc (NASDAQ)
Truck-O-Matic, Inc (NASDAQ)
Universal Health Services, Inc (NYSE)
Wherehouse Entertainment, Inc



Richard Berman’s business career spans over 35 years of venture capital, senior management, and merger & acquisitions experience. In the past 5 years, Berman has served as a director and/or officer of over a dozen public and private companies. In 2016, he was elected Chairman of Cevolva Biotech Inc. From 2006-2011, he was Chairman of National Investment Managers, a company with $12 billion in pension administration assets. Berman is a director of four public healthcare companies: Advaxis, Inc., BioVie, Inc., Cryoport, Inc., and BriaCell Therapeutics Corp. Recently, he becamr a director of Comsovereign. From 2002 to 2010, he was a director of Nexmed, Inc. (now Seelos Therapeutics, Inc.) where he also served as Chairman/CEO in 2008 and 2009. From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services) as Chairman and CEO, and was a director from 1998-2012.

Previously, Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; he created the largest battery company in the world, in the 1980’s, by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE); he helped create SoHo, the lower Manhattan neighborhood in NYC, by developing five buildings; and he advised on over $4 billion M&A transactions, completing over 300 deals.

Berman is a past Director of the Stern School of Business of NYU where he obtained his B.S. and
M.B.A. degrees. He also has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.

Berman is currently a director of four public healthcare companies and two other companies:

(1) BIOVIE INC. – BioVie has a therapy for advanced liver cirrhosis. The company is starting a P2b/3 clinical trial. Biovie anticipates a reverse stock split, a substantial raise and will apply for a NASDAQ listing in the second half of 2019.
(2) ADVAXIS, INC. (NASDAQ:ADXS) – The company has developed a P3 vaccine product to treat cervical cancer; and has products in P1 and P2 in the following areas: prostate, head and neck, lung, and anal cancer. The company uses multiple mechanisms of immunity to create more effective and safer cancer vaccines and has raised well over $200 million since October 2013. In July 2019, the Company raised $17 million.
(3) CRYOPORT, INC. (NASDAQ:CYRX) – The company is the leader in the cryogenics, logistics, and storage market in the pharmaceutical industry. Sales have grown from less than one million in 2014 to more than $40 million this year. The company has partnered with FedEx, UPS and DHL. The company’s objective is to reach sales of $100 million in the next two years.
(4) BRIACELL THERAPEUTICS CORP is a clinical stage company specializing in targeted immunotherapy for advanced breast cancer. The Company has had a remarkable response in combination with Keytruda.
(5) CUENTAS, INC. – Is a fintech company that serves the banking needs of 70 million immigrants in the U.S. Its services include phone cards, credit cards, money transfer and the like. The company utilizes proprietary technologies and partners with major corporations. In 2020, the company is expected to generate revenues of roughly $20 million.
(6) Comsovereign. With projected 2020 sales of over $100 million, the company is going public through a reverse merger with a successful public Co. The company is a leader in the drone, military and tele-communications field.